After Long Wait, Hospira Launches Generic Zosyn In US
21 Outubro 2010 - 6:54PM
Dow Jones News
Hospira Inc. (HSP) said Thursday it is finally launching a
generic version of Pfizer Inc.'s (PFE) injectable antibiotic Zosyn
in the U.S. after gaining approval of the Food and Drug
Administration.
Hospira, which already markets the generic drug in more than a
dozen markets outside the U.S., has been trying to years to bring
it to the home market. The Lake Forest, Ill., company estimated the
drug, known generically as piperacillin and tazobactam, posted U.S.
sales of more than $855 million last year.
Canada's Apotex Inc. also sells a generic version in the
U.S.
The launch for Hospira is "a clear positive," said Leerink Swann
analyst Rick Wise, who estimated generic Zosyn could add as much as
10 cents a share to Hospira's earnings next year. Hospira has a
manufacturing partnership with Novartis AG (NVS, NOVN.VX) unit
Sandoz for the drug, and Wise believes it entails a share of
profits, although Hospira declined to detail the terms.
Hospira shares climbed 2.5% to close at $59.45 Thursday.
The U.S. launch for generic Zosyn has been a long time coming
for Hospira, but with speed bumps along the way. Plans for a 2007
launch, for example, were hurt when the branded drug's maker
changed the formulation for safety reasons, causing headaches for
companies that had submitted applications to the FDA to compete
generically. Wyeth, which Pfizer later purchased, was the Zosyn
maker at that time.
-By Jon Kamp, Dow Jones Newswires; 617-654-6728;
jon.kamp@dowjones.com
Hospira (NYSE:HSP)
Gráfico Histórico do Ativo
De Jul 2024 até Ago 2024
Hospira (NYSE:HSP)
Gráfico Histórico do Ativo
De Ago 2023 até Ago 2024
Notícias em tempo-real sobre da New York Stock Exchange bolsa de valores: 0 artigos recentes
Mais Notícias de Hospira Inc.